ArticleTherapeutics and clinical risk management2010
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment.
Article in Therapeutics and clinical risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Endoscopic muscularis excavation for subepithelial tumors of the esophagogastric junction originating from the muscularis propria layer.Digestive diseases and sciences · 2013Trial
- Recent Advances in Endoscopic Treatment Techniques for Subepithelial Lesions.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Duodeno-duodenal intussusception due to gastrointestinal stromal tumor: A case report.SAGE open medical case reports · 2024Article
- Gastrointestinal Stromal Tumor Recurrence Presenting as a Small Bowel Obstruction: A Case Report.Cureus · 2023Article
- Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2020Article
- Implementing a Cloud Based Method for Protected Clinical Trial Data Sharing.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2020Article
- A rare case report of locally recurrent hemorrhagic duodenal gastrointestinal stromal tumor: therapeutic challenges and review of prognostic indicators for recurrence.Journal of surgical case reports · 2020Article
- Acute Right Lower Abdomen in a Patient with a History of Gastrointestinal Stromal Tumor.Case reports in surgery · 2019Article
- Endoscopic submucosal dissection for gastric gastrointestinal stromal tumors: a retrospective cohort study.Surgical endoscopy · 2017Article
- Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study.Cancer growth and metastasis · 2017Article
- C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach.Journal of gastric cancer · 2015Article
- Gastrointestinal Stromal Tumours: Review of 150 Cases from a Single Centre.The Indian journal of surgery · 2015Article
- Gastrointestinal stromal tumors.International journal of colorectal disease · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery with complete removal of the tumor is the primary treatment for resectable GIST and the only chance of cure. However, recurrence after surgery is common. The 2 main prognostic factors are the mitotic activity and the size of the tumor. Tumor rupture is also a risk factor for postoperative recurrence, and extra care should be taken while manipulating this soft and friable tumor. Imatinib mesylate (IM, Gleevec(®), Novartis, Basel, Switzerland) is a tyrosine kinase inhibitor and was first studied in the palliative setting for metastatic GIST patients in the year 2000. It is now the cornerstone of metastatic GIST treatment. IM also plays an important role as an adjuvant treatment for resectable GIST and has been shown to increase the recurrence-free survival in phase III studies. However, some points remain to be clarified. Notably, the ideal duration of adjuvant IM after surgery is still unclear. It is also difficult to determine the exact place of surgery in metastatic or recurrent GIST patients in the IM era. A multidisciplinary approach is, therefore, mandatory to offer GIST patients the best treatment available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.